Loxapine
لوکساپین
🧠 Nervous SystemDibenzoxazepine (typical antipsychotic)
Market / country: 🇺🇸 USA
Loxitane (US)
🧮 Dose calculator
Schizophrenia · Regimen source: FDA Loxapine · Dosage and Administration
- • Increase over 7–10 days; usual range 60–100 mg/day in 2–4 doses; not above 250 mg/day. Maintenance often 20–60 mg/day. FDA Loxapine · Dosage and Administration
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Coma or severe drug-induced depressed states (alcohol, barbiturates, opioids); hypersensitivity to dibenzoxazepines. FDA Loxapine · Contraindications
Warnings
- • Boxed warning: increased mortality in elderly patients with dementia-related psychosis — not approved for this use. FDA Loxapine · Warnings
Formulations
- 10 mg capsule — capsule 🇺🇸 USA FDA Loxapine · How Supplied
- 25 mg capsule — capsule 🇺🇸 USA FDA Loxapine · How Supplied
- 5 mg capsule — capsule 🇺🇸 USA FDA Loxapine · How Supplied
- 50 mg capsule — capsule 🇺🇸 USA FDA Loxapine · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Loxapine · Pregnancy
“Loxapine succinate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Loxapine · Nursing Mothers
“The extent of the excretion of loxapine or its metabolites in human milk is not known.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Loxapine · Pediatric Use
“Safety and effectiveness of loxapine in pediatric patients have not been established.”
- 👴 Older adultsDangerous / avoid
Label: serious warning or avoid in older adults. FDA Loxapine · Boxed Warning
“Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA072204
- DailyMed (FDA label)FDA Loxapine
- MedlinePlus (NIH)Loxapine
- WHO ATC/DDDN05AH01
- Darooyab (Iran)Loxapine
🇮🇷 Not found in Iran list Darooyab · G-1297/Loxapine
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Loxapine · How SuppliedFDA Loxapine · Dosage and AdministrationFDA Loxapine · ContraindicationsFDA Loxapine · WarningsFDA Loxapine · PregnancyFDA Loxapine · Nursing MothersFDA Loxapine · Pediatric UseFDA Loxapine · Boxed WarningFDA Loxapine · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1297/Loxapine
- Clinical review⚠ Unverified